Citation Impact
Citing Papers
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Hepatitis C virus drug resistance–associated substitutions: State of the art summary
2015
A Meta-Analysis of Cytokines in Major Depression
2009 Standout
Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis
2001
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
Influence of psychological stress on immune-inflammatory variables in normal humans. Part II. Altered serum concentrations of natural anti-inflammatory agents and soluble membrane antigens of monocytes and T lymphocytes
1999
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
QM/MM Methods for Biomolecular Systems
2009 Standout
Update on alisporivir in treatment of viral hepatitis C
2012
Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies
2016 StandoutNobel
Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis
2009 Standout
Multi-input chemical control of protein dimerization for programming graded cellular responses
2019 StandoutNobel
In vivo immunomodulatory effects of clozapine in schizophrenia
1997
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
2015
Modelling hepatitis C therapy—predicting effects of treatment
2015
Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?
2012
The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection
2011 Standout
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Super-resolution microscopy demystified
2018 Standout
Discovery of new chromone containing sulfonamides as potent inhibitors of bovine cytosolic carbonic anhydrase
2011
Hepatitis C Treatment: The Data Flood Goes on—An Update From the Liver Meeting 2014
2015
The role of resistance in HCV treatment
2012
Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy
2014
Cytokines sing the blues: inflammation and the pathogenesis of depression
2005 Standout
Pharmacological targeting of the HIF hydroxylases – A new field in medicine development
2016 StandoutNobel
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
2014
Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin
2015 StandoutNobel
How were new medicines discovered?
2011 Standout
Update on hepatitis C virus resistance to direct-acting antiviral agents
2014
Identification of rat prostatic steroid binding protein (PSBP) as an immunosuppressive factor
2001
Requirements for human Dicer and TRBP in microRNA-122 regulation of HCV translation and RNA abundance
2012
Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
2014
The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities
2015 Standout
Hepatitis C Virus: 30 Years after Its Discovery
2019 StandoutNobel
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
2011 Standout
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
2016
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
A Quantum Mechanics/Molecular Mechanics Study of the Protein–Ligand Interaction for Inhibitors of HIV‐1 Integrase
2007
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
2017 Standout
The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6
1998
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Psychological Stress and the Human Immune System: A Meta-Analytic Study of 30 Years of Inquiry.
2004 Standout
Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs
1996
Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results
2013
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Multi-Organ, Multi-Lineage Engraftment by a Single Bone Marrow-Derived Stem Cell
2001 Standout
Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics
2000
Hybrid Quantum Mechanical/Molecular Mechanical Molecular Dynamics Simulations of HIV-1 Integrase/Inhibitor Complexes
2007
Clinical relevance of HCV antiviral drug resistance
2012
Detection of a Sexually Transmitted Hepatitis C Virus Protease Inhibitor-Resistance Variant in a Human Immunodeficiency Virus–Infected Homosexual Man
2014
Lung Epithelium–specific Proteins
1999
Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus
2012
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
2013 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings
2021 Standout
Enhancement of hepatitis C viral RNA abundance by precursor miR-122 molecules
2013 StandoutNobel
Computing Clinically Relevant Binding Free Energies of HIV-1 Protease Inhibitors
2014
DOCK 6: Impact of new features and current docking performance
2015
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
Protease inhibitor therapy for hepatitis C virus-infection
2018
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications
2015
TMC647055, a Potent Nonnucleoside Hepatitis C Virus NS5B Polymerase Inhibitor with Cross-Genotypic Coverage
2012
Investigating Stem Cells in the Lung
1998
Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.
2012
Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors
2011
Applications of Binding Kinetics to Drug Discovery
2008
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Prevention of hepatitis C virus infection using a broad cross‐neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate
2015 StandoutNobel
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells
2019 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
2015 Standout
Deep Sequencing and Phylogenetic Analysis of Variants Resistant to Interferon-Based Protease Inhibitor Therapy in Chronic Hepatitis Induced by Genotype 1b Hepatitis C Virus
2015
Hoxb13is required for normal differentiation and secretory function of the ventral prostate
2003 StandoutNobel
Proteases and protease inhibitors in infectious diseases
2017
Passage of Inhaled Particles Into the Blood Circulation in Humans
2002 Standout
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
2017 Standout
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
2008
Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space
2016
Rational Design of Doravirine: From Bench to Patients
2019
Nanobodies: Natural Single-Domain Antibodies
2013 Standout
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
2014
Works of Inge Dierynck being referenced
Potent inhibition of both human interferon-gamma production and biologic activity by the Clara cell protein CC16.
1995
Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
2013
Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment
2014
Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial
2012
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
2009
A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional Nanobodies
2012
Deep-Sequencing Analysis of the Gene Encoding the Hepatitis C Virus Nonstructural 3–4A Protease Confirms a Low Prevalence of Telaprevir-Resistant Variants at Baseline and the End of the REALIZE Study
2014
Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
2012
The Impact of Individual Human Immunodeficiency Virus Type 1 Protease Mutations on Drug Susceptibility Is Highly Influenced by Complex Interactions with the Background Protease Sequence
2009
Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier
2007
1174 DEEP SEQUENCING SCREENING FOR TELAPREVIR-RESISTANT VIRAL VARIANTS IN PREVIOUS NULL RESPONDERS FAILS TO IDENTIFY THOSE PATIENTS AT RISK OF FAILING TELAPREVIR PLUS PEGINTERFERON/RIBAVIRIN THERAPY
2012
T-24 Retreatment with telaprevir/Peg-IFN/RBV after a short exposure to telaprevir in Phase I studies: interim results from a Phase IIIb rollover trial (C219)
2012
Design and Optimization of Tricyclic Phtalimide Analogues as Novel Inhibitors of HIV-1 Integrase
2004
Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes
2013
1202 CHARACTERISATION OF HCV VARIANTS IN NON-SVR PATIENTS IN THE REALIZE STUDY SUGGESTS THAT TELAPREVIR EXHIBITS A CONSISTENT RESISTANCE PROFILE IRRESPECTIVE OF A LEAD-IN
2011
The human Clara cell protein: biochemical and biological characterisation of a natural immunosuppressor
1996
8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS
2011
Crystal Structure of Lysine Sulfonamide Inhibitor Reveals the Displacement of the Conserved Flap Water Molecule in Human Immunodeficiency Virus Type 1 Protease
2007
898 TREATMENT WITH TELAPREVIR/PEG-IFN/RBV AFTER 14-DAY TELAPREVIR EXPOSURE IN PHASE I STUDIES: RESULTS FROM THE PHASE IIIB C219 ROLLOVER STUDY
2013